<p>Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain</p>

Josep‐María Ribera(Universitat Autònoma de Barcelona), Cristina Díaz de Heredia(Universitat Autònoma de Barcelona), Diana Martínez Llinàs(Oblikue Consulting (Spain)), Alejandra de Andrés Saldaña(Novartis (Spain)), Joana Gostkorzewicz(Novartis (Spain)), Núria García-Muñoz(Accenture (Spain))
ClinicoEconomics and Outcomes Research
May 1, 2020
Cited by 27


Related Papers